Niox Group PLC
LSE:NIOX

Watchlist Manager
Niox Group PLC Logo
Niox Group PLC
LSE:NIOX
Watchlist
Price: 61.4 GBX -2.85%
Market Cap: 244.4m GBX
Have any thoughts about
Niox Group PLC?
Write Note

Niox Group PLC
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Niox Group PLC
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Niox Group PLC
LSE:NIOX
Income from Continuing Operations
ÂŁ11m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Income from Continuing Operations
-$151.1m
CAGR 3-Years
-142%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Income from Continuing Operations
-$208.4m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Income from Continuing Operations
-$166.3m
CAGR 3-Years
-36%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Income from Continuing Operations
-ÂŁ55.3m
CAGR 3-Years
9%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Income from Continuing Operations
ÂŁ2.4m
CAGR 3-Years
-63%
CAGR 5-Years
-19%
CAGR 10-Years
-22%
No Stocks Found

Niox Group PLC
Glance View

Market Cap
260.4m GBX
Industry
Biotechnology

Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The Company’s product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The firm offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The firm provides products and services in around 50 countries.

NIOX Intrinsic Value
48.28 GBX
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Niox Group PLC's Income from Continuing Operations?
Income from Continuing Operations
11m GBP

Based on the financial report for Jun 30, 2024, Niox Group PLC's Income from Continuing Operations amounts to 11m GBP.

What is Niox Group PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 1Y
36%

Over the last year, the Income from Continuing Operations growth was 36%.

Back to Top